PENDING GLAIMS AFTER AMENDMENT

1. Compounds of the Formula



(I) wherein

X is H_2N-C (=NH) - or R^1-N=C (-NH_2)- , wherein
R^1 is -OH, -C(=O)OR^2, alkyl, aralkyl, aralkyloxy or a heteroalkyl group, such as alkyloxy, acyl or acyloxy, wherein
R^2 is alkyl, heteroalkyl, carbocyclic, heterocycloalkyl, aryl, heteroaryl or aralkyl;

Ar is arylene, heteroarylene, or aralkylene wherein X is directly attached to the aromatic ring system;

R^3 is H, alkyl, heteroalkyl or aralkyl;

R^4 is H, an alkyl group which may be substituted with one or more -OH or -NH_2 groups, a heteroalkyl group, a carbocyclic group, a heterocycloalkyl group, an aryl group, a heteroaryl group or an aralkyl group, which groups may be substituted with one or more groups selected from alkyl, heteroalkyl such as alkyloxy, acyl or acyloxy, a carbocyclic group, heterocycloalkyl, aryl, heteroaryl or aralkyl;

R^5 is H, alkyl, heteroalkyl, carbocyclic, heterocycloalkyl, aryl, heteroaryl or aralkyl;

R^6 and R^7 are independently H, alkyl, heteroalkyl, carbocyclic, heterocycloalkyl such as aryl-heterocycloalkyl, aryl, heteroaryl, aralkyl or heteroarylalkyl, which groups may be

substituted with one or more groups selected from alkyl, heteroalkyl such as alkoxy, acyl or acyloxy, a carbocyclic group, heterocycloalkyl, aryl, heteroaryl, aralkyl, -OH or $-NH_2$, or are members of a heterocycloalkyl ring system, in particular an aryl-heterocycloalkyl ring system, or a heteroaryl ring system, which systems may be substituted with one or more groups selected from alkyl, heteroalkyl such as alkoxy, acyl or acyloxy, a carbocyclic group, heterocycloalkyl, aryl, heteroaryl, aralkyl, -OH or $-NH_2$; and

R^8 is H, alkyl, heteroalkyl, carbocyclic, heterocycloalkyl, aryl, heteroaryl or aralkyl;

or a pharmacologically acceptable salt, solvate, hydrate or formulation thereof.

2. Compounds according to Claim 1, wherein

X is H_2N-C (=NH) - or R^1-N=C ($-NH_2$) - ;
wherein R^1 is -OH or -C (=O) OR^2;
wherein R^2 is alkyl, heteroalkyl, carbocyclic, heterocycloalkyl, aryl, heteroaryl or aralkyl;

Ar is arylene, heteroarylene, or aralkylene;

R^3 is H, alkyl, heteroalkyl or aralkyl;

R^4 is H, alkyl which may be substituted with -OH or $-NH_2$ groups, heteroalkyl, carbocyclic, carboxyalkyl ester, heterocycloalkyl, aryl which may be substituted with acyl groups, heteroaryl or aralkyl;

R^5 is H, alkyl, heteroalkyl, carbocyclic, or aralkyl;

R^6 and R^7 are independently H, alkyl, heteroalkyl, carbocyclic, heterocycloalkyl, aryl, heteroaryl, arylheterocycloalkyl which may be substituted with acyl groups, heteroalkylaryl which may be substituted with alkyl groups, aralkyl which may be

substituted with acyl groups, or are members of the same heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl which may be substituted with alkylene groups, or aralkyl ring system, which may be substituted with -OH or $-NH_2$ groups; and

R^8 is H;

or a pharmaceutically acceptable salt, solvate, hydrate or formulation thereof.

3. Compounds according to Claim 1 or 2, wherein
X is H_2N-C (=NH) - or HO-N=C(-NH_2) - or R^2OC (=O) -N=C (-NH_2) - ,
R^3 is H,
Ar is meta-phenylene, and
R^5 is a small alkyl or an aralkyl group.

4. (amended) Compounds according to Claim 1 [Claims 1 to 3], wherein
X is H_2N-C (=NH) - or HO-N=C(-NH_2) - or R^2OC (=O) -N=C (-NH_2) - ,
R^3 is H,
R^4 is H, methyl, hydroxymethyl, isopropyl, 2-imidazolyl, 3-pyrazolyl,
Ar is meta-phenylene,
R^5 is a small alkyl or an aralkyl group, and
R^8 is H.

5. (amended) Compounds according to Claim 1 [Claims 1 to 4], wherein
X is H_2N-C (=NH) - or HO-N=C(-NH_2) - or R^2OC (=O) -N=C (-NH_2) - ,
R^3 is H,
R^4 is H, methyl, hydroxymethyl, 1,2-dihydroxyethyl, ethoxycarbonyl, isopropyl, cyclopropyl, 2-imidazolyl, 2-pyrrolyl, 3-pyrazolyl, 2-pyridyl, 4-methoxycarbonylphenyl,
Ar is meta-phenylene,
R^5 is a small alkyl or an aralkyl group,
R^6 is H and R^7 is optionally substituted 1H-indol-3-yl-ethyl, 4-hydroxy-phenylethyl,

cyclohexyl, N-(2-methoxyphenyl)piperazinyl, 1,3-benzodioxol-5-ylmethyl, benzyl, phenethyl, 3,4-dimethoxyphenyl-1-ylmethyl, 2-methoxyphenyl-1-ylmethyl, 2-(4-morpholinyl)ethyl, 2-pyridinylethyl, 2-pyridinylpropyl, 3-pyridinylmethyl or R^6 and R^7 are part of a tetrahydroisoquinoline ring, a 4-thiomorpholine ring, a N-(2-methoxyphenyl)piperazine ring or a N-(4-methoxyphenyl)piperazine ring, and
R^8 is H

6. Compounds according to Claim 1, wherein
X is H_2N-C (=NH) - or HO-N=C ($-NH_2$) or R^2OC (=O) -N=C($-NH_2$) - ,
R^3 is H,
Ar is para-phenylmethylene group, and
R^5 is a small alkyl or an aralkyl group.

7. (amended) Compounds according to Claims 1 or [and] 6, wherein
X is H_2N-C (=NH) - or HO-N=C($-NH_2$) - or R^2OC (=O) -N=C ($-NH_2$) - ,
R^3 is H,
R^4 is H, methyl, hydroxymethyl, isopropyl, 2-imidazolyl, 3-pyrazolyl,
Ar is para-phenylmethylene group, and
R^5 is a small alkyl or an aralkyl group.

8. (amended) Compounds according to Claims 1 or 6 [1, 6 and 7], wherein
X is H_2N-C (=NH) - or HO-N=C($-NH_2$) - or R^2OC (=O) -N=C ($-NH_2$) - ,
R^3 is H,
R^4 is H, methyl, hydroxymethyl, 1,2-dihydroxyethyl, ethoxycarbonyl, isopropyl, cyclopropyl, 2-imidazolyl, 2-pyrrolyl, 3-pyrazolyl, 3- or 4-phenoxy-phenyl, 1,3-benzodioxol-5-yl, 2-pyridyl, 4-methoxycarbonyl-phenyl,
Ar is para-phenylmethylene group,
R^5 is a small alkyl or an aralkyl group,
R^6 is H and R^7 is optionally substituted 1H-indol-3-yl-ethyl, 4-hydroxy-phenethyl, cyclohexyl, N-(2-methoxyphenyl)piprazinyl, 1,3-benzodioxol-5-ylmethyl, benzyl,

phenethyl, 3,4-dimethoxyphenyl-1-ylmethyl, 2-methoxyphenyl-1-ylmethyl, 2-(4-morpholinyl)ethyl, 2-pyridinylethyl, 2-pyridinylpropyl, 3-pyridinylmethyl or R^6 and R^7 are part of a tetrahydroisoquinoline ring, a 4-thiomorpholine ring, a N-(2-methoxyphenyl)piperazine ring or a N-(4-methoxyphenyl)piperazine ring, and R^8 is H.

9. (amended) A pharmaceutical composition [Pharmaceutical compositions] containing a compound according to Claim 1 or 2 [Claims 1 to 8] as the active agent and optionally carriers and/or adjuvants.